China's ongoing battle with viral hepatitis has emerged as a compelling case study for countries like India that face similar public health challenges. With approximately 80 million hepatitis B carriers and millions affected by hepatitis C, China has implemented large-scale interventions that offer practical lessons for India's healthcare system.
Understanding the Hepatitis Challenge
Viral hepatitis, particularly hepatitis B and C, represents a silent epidemic across Asia. The diseases often progress without obvious symptoms, leading to chronic liver disease, cirrhosis, and liver cancer over decades. Both China and India share risk factors including high population density, variable healthcare access, and historical gaps in blood safety protocols.
India currently has an estimated 40 million people living with chronic hepatitis B and 6-12 million with hepatitis C. Despite these significant numbers, hepatitis has received far less attention than diseases like tuberculosis or HIV/AIDS in national health programmes.
China's Strategic Approach
China's response to hepatitis has evolved significantly over the past two decades. The country integrated hepatitis B vaccination into its national immunisation programme in 2002, providing free vaccines to all newborns. This single intervention has dramatically reduced new infections among children.
Beyond vaccination, China established comprehensive screening programmes, particularly focusing on pregnant women to prevent mother-to-child transmission. The country also invested heavily in public awareness campaigns to reduce stigma and discrimination against hepatitis carriers, which had been a significant barrier to testing and treatment.
China's approach also included strict regulations on blood safety, mandatory screening of blood products, and the elimination of paid blood donation, which had been a major transmission route.
Key Lessons for India
India's public health infrastructure can benefit from several elements of China's hepatitis control strategy:
- Universal birth dose vaccination coverage with proper cold chain maintenance across rural and remote areas
- Integration of hepatitis screening into routine antenatal care services
- Strengthening blood bank regulations and ensuring 100% screened blood supply
- Developing clear treatment protocols and making antiviral medications affordable and accessible
- Creating robust disease surveillance systems to track infection rates and treatment outcomes
The Vaccination Gap
While India introduced hepatitis B vaccination in 2002-2003, coverage remains inconsistent. The crucial birth dose, which must be administered within 24 hours of delivery, reaches only about 60% of newborns nationally. China's success in achieving over 95% birth dose coverage through community health workers and facility-based deliveries demonstrates the importance of last-mile delivery mechanisms.
India needs to prioritise home births and remote areas where vaccination coverage is weakest. Training auxiliary nurse midwives and ASHA workers to administer birth doses safely could significantly improve outcomes.
Building Awareness and Reducing Stigma
Public awareness about hepatitis transmission, prevention, and treatment remains low in India. Many people discover their infection status only when serious liver complications develop. China's multi-channel awareness campaigns, including school education programmes and workplace screening initiatives, helped normalise testing and treatment-seeking behaviour.
India could leverage its successful HIV/AIDS awareness models to create similar hepatitis education programmes, emphasising that hepatitis B and C are manageable conditions when detected early.
Strengthening Healthcare Infrastructure
China's investment in viral hepatitis research centres, specialist training programmes, and laboratory networks has created a robust ecosystem for disease management. India's medical colleges and research institutions could establish similar centres of excellence focused on hepatitis care.
The integration of hepatitis services into existing programmes like the National Health Mission could improve efficiency without requiring entirely new infrastructure.
Treatment Accessibility
The availability of affordable generic antiviral medications has been a game-changer for hepatitis C treatment globally. India's pharmaceutical manufacturing capabilities position it well to ensure treatment access, but healthcare delivery systems must be strengthened to diagnose patients and initiate therapy.
China's tiered healthcare approach, where primary health centres handle screening and basic management while complex cases are referred to specialist facilities, offers a practical model for resource-optimised care delivery.
Moving Forward
India's public health system has demonstrated remarkable capability in implementing large-scale programmes, from polio eradication to COVID-19 vaccination. Applying similar focus and resources to viral hepatitis control could prevent millions of future liver disease cases and deaths.
The lessons from China's experience underscore that hepatitis control requires sustained political commitment, adequate funding, and coordinated action across prevention, diagnosis, and treatment domains.
This article is for general informational purposes only and does not constitute medical advice. Readers should consult qualified healthcare professionals for diagnosis, treatment, and medical guidance regarding hepatitis or any other health condition.
